ASL in Brain Metastasis MRI Following Gamma Knife Treatment

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Apr 2, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new MRI technique called arterial spin labeling (ASL) to help doctors determine whether brain metastases (cancer that has spread to the brain) are growing or if they are just showing signs of damage from a previous treatment called gamma knife therapy. The goal is to see how effective ASL is in distinguishing between these two conditions, which is important for deciding the best treatment for patients.

To be eligible for this study, participants should be between the ages of 65 and 74 and have a confirmed diagnosis of brain metastasis that has been treated with gamma knife therapy within the last four months. They should have lesions (tumor areas) that are suspected of growing or causing damage, and these lesions must be at least 1 cm in size. If you are pregnant, have certain medical conditions, or are participating in other studies, you may not be able to join. Those who participate can expect to undergo a non-invasive MRI scan that is designed to provide important information about their condition without any needles or surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Brain metastasis from histologically proven tumor
• • GK treatment within 4 month prior to the inclusion
• * Lesions suspected of progression/ radionecrosis :
• • i.e.≥ 25% of the size progression
• • Lesion size: gadolinium enhanced part of the tumour ≥1 cm
• Exclusion Criteria:
• • Pregnancy
• • Medical history of primitive brain tumour
• • MRI incompatibility/ medical history of contrast agent allergy
• • Claustrophobia
• • Patient unable to consent
• • Epilepsia/recent stroke
• • Patients participating in other studies
• • Patients without health care insurance